Hadebe, S;
Chengalroyen, M;
Guler, R;
Nakedi, K;
Koch, A;
Makatsa, M;
Shey, M;
... Ndlovu, H; + view all
(2020)
Intervening along the spectrum of tuberculosis: meeting report from the World TB Day nanosymposium in the Institute of Infectious Disease and Molecular Medicine at the University of Cape Town [version 4; peer review: 2 approved].
Gates Open Research
, 3
, Article 1491. 10.12688/gatesopenres.13035.4.
Preview |
Text
f414f83f-4ca5-44ae-8b5a-bac9acef7dc0_13035_-_sabelo_hadebe_v4.pdf - Published Version Download (291kB) | Preview |
Abstract
Tuberculosis (TB), caused by the highly infectious Mycobacterium tuberculosis, remains a leading cause of death worldwide, with an estimated 1.6 million associated deaths reported in 2017. In South Africa, an estimated 322,000 (range 230,000-428,000) people were infected with TB in 2017, and a quarter of them lost their lives due to the disease. Bacille Calmette-Guérin (BCG) remains the only effective vaccine against disseminated TB, but its inability to confer complete protection against pulmonary TB in adolescents and adults calls for an urgent need to develop new and better vaccines. There is also a need to identify markers of disease protection and develop novel drugs. It is within this backdrop that we convened a nanosymposium at the Institute of Infectious Disease and Molecular Medicine at the University of Cape Town to commemorate World TB Day and showcase recent findings generated by early career scientists in the institute. The speakers spoke on four broad topics: identification of novel drug targets, development of host-directed drug therapies, transmission of TB and immunology of TB/HIV co-infections.
| Type: | Article |
|---|---|
| Title: | Intervening along the spectrum of tuberculosis: meeting report from the World TB Day nanosymposium in the Institute of Infectious Disease and Molecular Medicine at the University of Cape Town [version 4; peer review: 2 approved] |
| Location: | United States |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.12688/gatesopenres.13035.4 |
| Publisher version: | https://doi.org/10.12688/gatesopenres.13035.4 |
| Language: | English |
| Additional information: | Copyright © 2020 Hadebe S et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| Keywords: | Host directed Therapies, TB/HIV co-infections, Tuberculosis, new tools, transmission |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Infection and Immunity |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10101494 |
Archive Staff Only
 |
View Item |
